Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607284 | 1.00 | HTR2A (0.91) | HTR2ADRD3 | |
| SCHEMBL606565 | 0.95 | HTR2A (1.00) | HTR2ADRD3 | |
| SCHEMBL10164378 | 0.95 | HTR2A (1.00) | HTR2ADRD3 | |
| SCHEMBL10164435 | 0.94 | HTR2A (1.00) | HTR2ADRD3 | |
| SCHEMBL608075 | 0.94 | HTR2A (1.00) | HTR2ADRD3 | |
| SCHEMBL608074 | 0.94 | HTR2A (1.00) | HTR2ADRD3 | |
| SCHEMBL607314 | 0.94 | HTR2A (1.00) | HTR2ADRD3 | |
| SCHEMBL605580 | 0.94 | HTR2A (1.00) | HTR2ADRD3 | |
| SCHEMBL15866499 | 0.94 | HTR2A (1.00) | HTR2ADRD3 | |
| SCHEMBL605581 | 0.94 | HTR2A (1.00) | HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183245-B1 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-07-09 | — | — | EP | claimed |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | claimed |
| EP-2183245-B1 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20120040972-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040972-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | HTR2A 1/4885DRD3 10/4885 |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | HTR2A 1/4885DRD3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.